Please login to the form below

Not currently logged in
Email:
Password:

Dapagliflozin meets goals of late-stage study

Bristol-Myers Squibb and AstraZeneca's diabetes drug dapagliflozin has met the main goals of a phase III trial

BMS and AZ's diabetes drug dapagliflozin met the main goals of a phase III trial. It was proven that the drug was more effective than an older treatment at reducing blood sugar levels.

Dapagliflozin is a first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor being developed as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes.

The trial enrolled 597 patients with type 2 diabetes that was inadequately controlled with at least half the recommended dose of glimepiride. The companies said a combination of dapagliflozin and glimepiride was better at reducing blood sugar levels than glimepiride and a placebo.

Patients on dapagliflozin also lost more weight, had greater oral glucose tolerance and lower blood sugar levels between meals after the 24-week late stage clinical trial.

Side-effects were similar for dapagliflozin and glimepiride, but patients on dapagliflozin were more likely to have genital tract infections.

Results from the trial were presented at a meeting of the European Association for the Study of Diabetes in Stockholm.

21st September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics